CLINICAL_TRIALS
trial_result
· 2024-07-03
Clinical Trial Update: A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy [Phase 3]
Summary
Phase 3 study evaluating sparsentan for IgA nephropathy has posted results in July 2024; the trial is currently not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Travere Therapeutics, Inc. | Conditions: Immunoglobulin A Nephropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-03